Neurodegenerative Disease Research
Cyclo Therapeutics Inc. focuses on clinical research in early Alzheimer’s disease, with attention to therapeutic options aimed at preserving cognitive function and addressing disease progression in the early stages of illness.
- Alzheimer’s disease
- Cognitive impairment
- Neuroprotection
Its work in this area reflects interest in treatments designed for patients with early symptomatic neurodegeneration.
Rare Lysosomal Storage Disorder Research
The sponsor is also active in Niemann-Pick disease type C1, a rare inherited disorder associated with abnormal cholesterol transport and progressive neurological involvement.
- Niemann-Pick disease type C1
- Lysosomal storage disorder
- Neurological progression
This therapeutic area includes interest in measures that track disease severity and functional change in patients with NPC1.
Intravenous Cyclodextrin Therapy
Clinical development activities include investigation of hydroxypropyl beta cyclodextrin as a treatment approach in both Alzheimer’s disease and NPC1, with emphasis on central nervous system-related therapeutic effects.
- Hydroxypropyl beta cyclodextrin
- Infusion-based therapy
- Central nervous system disorders
These studies align with the sponsor’s interest in therapies for conditions involving neurological dysfunction and altered lipid handling.
Neurology and Rare Disease Clinical Development
The sponsor’s research portfolio spans neurology and rare disease therapeutics, with activity across multiple countries and collaborating research sites supporting patient access in specialized disease areas.
- Neurology
- Rare disease therapeutics
- Specialty clinical research
Its medical interests center on conditions with limited treatment options, particularly disorders affecting cognition and progressive neurologic function.
